Tenax Therapeutics to Present at 2026 Cantor Global Healthcare Conference

CHAPEL HILL, N.C., Sept. 01, 2026 /CourierPR/ -- Tenax Therapeutics, a Phase 3 development-stage pharmaceutical company, is set to participate in the upcoming 2026 Cantor Global Healthcare Conference. On September 9, 2026, at 8:35 a.m. Eastern Time, the company’s President and CEO, Chris Giordano, will present at the event.

The presentation will be available for live streaming and later archiving through the company’s investor relations webpage. This event, which aims to bring together industry leaders and healthcare professionals, provides Tenax Therapeutics with an opportunity to showcase its advancements and strategies in the field of cardiopulmonary therapies.

Tenax Therapeutics focuses on developing novel treatments for cardiopulmonary conditions, particularly targeting PH-HFpEF (pulmonary hypertension associated with heart failure with preserved ejection fraction), a condition that remains unaddressed by any currently available drugs. Levosimendan, a compound owned by the company, is at the center of its research and development efforts, with the potential to significantly impact the treatment landscape for this prevalent condition.

For more information on Tenax Therapeutics and its initiatives, visit the company’s official website at www.tenaxthera.com. The firm's common stock is listed on The Nasdaq Stock Market under the ticker symbol “TENX.”